---
document_datetime: 2025-12-02 05:25:04
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/rekovelle.html
document_name: rekovelle.html
version: success
processing_time: 0.110242
conversion_datetime: 2025-12-25 00:08:16.448123
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Rekovelle

[RSS](/en/individual-human-medicine.xml/66173)

##### Authorised

This medicine is authorised for use in the European Union

follitropin delta Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Rekovelle](#news-on)
- [Related information](#related-information-638)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Rekovelle. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Rekovelle.

For practical information about using Rekovelle, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Rekovelle and what is it used for?

Rekovelle is a medicine given to women who are having fertility treatments such as in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI). It is used to stimulate the ovaries to produce several eggs at the time, which can then be collected and fertilised in the laboratory.

Rekovelle contains the active substance follitropin delta.

## How is Rekovelle used?

Rekovelle is available as a solution for injection, contained in a cartridge to be used with Rekovelle injection pen. The medicine can only be obtained with a prescription and treatment should be started under the supervision of a doctor who has experience in the treatment of fertility problems.

Rekovelle is given by injection under the skin once a day for several consecutive days during the woman's menstrual cycle starting on day 2 or 3 of the cycle and is continued until sufficient eggs have developed. The starting dose of Rekovelle depends on the woman's bodyweight and on the blood level of the anti-Müllerian hormone (a hormone which indicates how well the ovaries will respond to stimulation). The dose can then be modified in subsequent cycles according to the woman's response. After the first injection, the woman or their partner may be able to give the injections themselves, if they have been trained and have access to expert advice.

For further information, see the package leaflet.

## How does Rekovelle work?

The active substance in Rekovelle, follitropin delta, is a copy of the natural hormone called follicle-stimulating hormone (FSH) which plays a key role in fertility in women by stimulating the production of eggs in the ovaries. Giving extra stimulation with Rekovelle helps increase the number of eggs produced in the ovaries, which means that more eggs can then be collected and fertilised in the laboratory.

## What benefits of Rekovelle have been shown in studies?

Rekovelle was compared with GONAL-f (follitropin alfa), another fertility medicine, in one study involving 1,326 women who were undergoing controlled ovarian stimulation for IVF or ICSI. The main measure of effectiveness was the rate of implantation and pregnancy.

The study showed that Rekovelle was as effective as GONAL-f at stimulating the ovaries: around 31% of women (204 out of 665) treated with Rekovelle became pregnant compared with around 32% of women (209 out of 661) treated with GONAL-f. Implantation rates were also similar: around 35% with Rekovelle versus around 36% with GONAL-f.

## What are the risks associated with Rekovelle?

The most common side effects with Rekovelle (which may affect between 1 and 10 people in 100) are headache, discomfort and pain in the pelvic area which may arise from the ovaries, nausea (feeling sick) and tiredness and ovarian hyperstimulation syndrome (OHSS). OHSS is when a woman's ovaries over-respond to stimulation, causing symptoms such as vomiting, diarrhoea and pain. In severe cases OHSS may lead to difficulty breathing and problems with blood clotting. The frequency of side effects may decrease with repeated treatment cycles. For the full list of all side effects reported with Rekovelle, see the package leaflet.

Rekovelle must not be used in women with tumours of the pituitary gland or hypothalamus, or cancer of the breast, womb or ovary. Rekovelle must not be used when there is enlargement of an ovary or a cyst that is caused by something other than polycystic ovarian syndrome, or when there is unexplained bleeding from the vagina. For the full list of restrictions, see the package leaflet.

## Why is Rekovelle approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Rekovelle's benefits are greater than its risks and recommended that it be approved for use in the EU.

The CHMP considered that Rekovelle was effective in obtaining several eggs at the same time following stimulation in women undergoing fertility treatment. The safety profile of Rekovelle was considered acceptable and similar to that of GONAL-f.

## What measures are being taken to ensure the safe and effective use of Rekovelle?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rekovelle have been included in the summary of product characteristics and the package leaflet.

## Other information about Rekovelle

The European Commission granted a marketing authorisation valid throughout the European Union for Rekovelle on 12 December 2016.

For more information about treatment with Rekovelle, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Rekovelle : EPAR - Summary for the public

Reference Number: EMA/684112/2016

English (EN) (78 KB - PDF)

**First published:** 27/01/2017

**Last updated:** 27/01/2017

[View](/en/documents/overview/rekovelle-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-154)

български (BG) (103.55 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

27/01/2017

[View](/bg/documents/overview/rekovelle-epar-summary-public_bg.pdf)

español (ES) (76.5 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

27/01/2017

[View](/es/documents/overview/rekovelle-epar-summary-public_es.pdf)

čeština (CS) (103.58 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

27/01/2017

[View](/cs/documents/overview/rekovelle-epar-summary-public_cs.pdf)

dansk (DA) (76.09 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

27/01/2017

[View](/da/documents/overview/rekovelle-epar-summary-public_da.pdf)

Deutsch (DE) (77.63 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

27/01/2017

[View](/de/documents/overview/rekovelle-epar-summary-public_de.pdf)

eesti keel (ET) (76.24 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

27/01/2017

[View](/et/documents/overview/rekovelle-epar-summary-public_et.pdf)

ελληνικά (EL) (104.42 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

27/01/2017

[View](/el/documents/overview/rekovelle-epar-summary-public_el.pdf)

français (FR) (78.37 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

27/01/2017

[View](/fr/documents/overview/rekovelle-epar-summary-public_fr.pdf)

hrvatski (HR) (97.29 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

27/01/2017

[View](/hr/documents/overview/rekovelle-epar-summary-public_hr.pdf)

italiano (IT) (76.69 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

27/01/2017

[View](/it/documents/overview/rekovelle-epar-summary-public_it.pdf)

latviešu valoda (LV) (99.59 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

27/01/2017

[View](/lv/documents/overview/rekovelle-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (99.94 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

27/01/2017

[View](/lt/documents/overview/rekovelle-epar-summary-public_lt.pdf)

magyar (HU) (97.25 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

27/01/2017

[View](/hu/documents/overview/rekovelle-epar-summary-public_hu.pdf)

Malti (MT) (102.75 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

27/01/2017

[View](/mt/documents/overview/rekovelle-epar-summary-public_mt.pdf)

Nederlands (NL) (77.34 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

27/01/2017

[View](/nl/documents/overview/rekovelle-epar-summary-public_nl.pdf)

polski (PL) (105.15 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

27/01/2017

[View](/pl/documents/overview/rekovelle-epar-summary-public_pl.pdf)

português (PT) (77.15 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

27/01/2017

[View](/pt/documents/overview/rekovelle-epar-summary-public_pt.pdf)

română (RO) (99.25 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

27/01/2017

[View](/ro/documents/overview/rekovelle-epar-summary-public_ro.pdf)

slovenčina (SK) (101.82 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

27/01/2017

[View](/sk/documents/overview/rekovelle-epar-summary-public_sk.pdf)

slovenščina (SL) (95.82 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

27/01/2017

[View](/sl/documents/overview/rekovelle-epar-summary-public_sl.pdf)

Suomi (FI) (75.88 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

27/01/2017

[View](/fi/documents/overview/rekovelle-epar-summary-public_fi.pdf)

svenska (SV) (77.88 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

27/01/2017

[View](/sv/documents/overview/rekovelle-epar-summary-public_sv.pdf)

## Product information

Rekovelle : EPAR - Product Information

English (EN) (969.42 KB - PDF)

**First published:** 27/01/2017

**Last updated:** 04/10/2023

[View](/en/documents/product-information/rekovelle-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-651)

български (BG) (1.03 MB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/bg/documents/product-information/rekovelle-epar-product-information_bg.pdf)

español (ES) (954.68 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/es/documents/product-information/rekovelle-epar-product-information_es.pdf)

čeština (CS) (1.11 MB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/cs/documents/product-information/rekovelle-epar-product-information_cs.pdf)

dansk (DA) (1003.3 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/da/documents/product-information/rekovelle-epar-product-information_da.pdf)

Deutsch (DE) (1.06 MB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/de/documents/product-information/rekovelle-epar-product-information_de.pdf)

eesti keel (ET) (1.08 MB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/et/documents/product-information/rekovelle-epar-product-information_et.pdf)

ελληνικά (EL) (1 MB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/el/documents/product-information/rekovelle-epar-product-information_el.pdf)

français (FR) (1.06 MB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/fr/documents/product-information/rekovelle-epar-product-information_fr.pdf)

hrvatski (HR) (1 MB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/hr/documents/product-information/rekovelle-epar-product-information_hr.pdf)

íslenska (IS) (975.48 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/is/documents/product-information/rekovelle-epar-product-information_is.pdf)

italiano (IT) (948.81 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/it/documents/product-information/rekovelle-epar-product-information_it.pdf)

latviešu valoda (LV) (915.2 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/lv/documents/product-information/rekovelle-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.19 MB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/lt/documents/product-information/rekovelle-epar-product-information_lt.pdf)

magyar (HU) (1.13 MB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/hu/documents/product-information/rekovelle-epar-product-information_hu.pdf)

Malti (MT) (1.08 MB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/mt/documents/product-information/rekovelle-epar-product-information_mt.pdf)

Nederlands (NL) (1.15 MB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/nl/documents/product-information/rekovelle-epar-product-information_nl.pdf)

norsk (NO) (1.53 MB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/no/documents/product-information/rekovelle-epar-product-information_no.pdf)

polski (PL) (1.27 MB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/pl/documents/product-information/rekovelle-epar-product-information_pl.pdf)

português (PT) (961.29 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/pt/documents/product-information/rekovelle-epar-product-information_pt.pdf)

română (RO) (1.14 MB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/ro/documents/product-information/rekovelle-epar-product-information_ro.pdf)

slovenčina (SK) (1.02 MB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/sk/documents/product-information/rekovelle-epar-product-information_sk.pdf)

slovenščina (SL) (1.07 MB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/sl/documents/product-information/rekovelle-epar-product-information_sl.pdf)

Suomi (FI) (1.01 MB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/fi/documents/product-information/rekovelle-epar-product-information_fi.pdf)

svenska (SV) (850.14 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

04/10/2023

[View](/sv/documents/product-information/rekovelle-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0037/G 20/07/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Rekovelle : EPAR - All Authorised presentations

English (EN) (12.82 KB - PDF)

**First published:** 27/01/2017

**Last updated:** 13/08/2021

[View](/en/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-107)

български (BG) (38.17 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/bg/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_bg.pdf)

español (ES) (13.63 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/es/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_es.pdf)

čeština (CS) (35.85 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/cs/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (12.96 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/da/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (13.16 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/de/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (12.82 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/et/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (36.35 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/el/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_el.pdf)

français (FR) (13.09 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/fr/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (22.56 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/hr/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (13.03 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/is/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_is.pdf)

italiano (IT) (13.58 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/it/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (36.91 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/lv/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (33.89 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/lt/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (30.34 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/hu/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (32.55 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/mt/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (12.93 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/nl/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (13.05 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/no/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_no.pdf)

polski (PL) (33.29 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/pl/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_pl.pdf)

português (PT) (13.07 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/pt/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_pt.pdf)

română (RO) (34.34 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/ro/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (34.34 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/sk/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (15.51 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/sl/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (12.72 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/fi/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (13.7 KB - PDF)

**First published:**

27/01/2017

**Last updated:**

13/08/2021

[View](/sv/documents/all-authorised-presentations/rekovelle-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Rekovelle Active substance follitropin delta International non-proprietary name (INN) or common name follitropin delta Therapeutic area (MeSH) Anovulation Anatomical therapeutic chemical (ATC) code G03GA10

### Pharmacotherapeutic group

Sex hormones and modulators of the genital system

### Therapeutic indication

Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle.

## Authorisation details

EMA product number EMEA/H/C/003994 Marketing authorisation holder

Ferring Pharmaceuticals A/S

Amager Strandvej 405

Marketing authorisation issued 12/12/2016 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Rekovelle : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (199.18 KB - PDF)

**First published:** 29/06/2017

**Last updated:** 03/10/2023

[View](/en/documents/procedural-steps-after/rekovelle-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Rekovelle : EPAR - Public assessment report

Adopted

Reference Number: EMA/11072/2017

English (EN) (1.97 MB - PDF)

**First published:** 27/01/2017

**Last updated:** 27/01/2017

[View](/en/documents/assessment-report/rekovelle-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Rekovelle

Adopted

Reference Number: EMA/CHMP/635107/2016

English (EN) (68.49 KB - PDF)

**First published:** 14/10/2016

**Last updated:** 14/10/2016

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-rekovelle_en.pdf)

#### News on Rekovelle

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-october-2016) 14/10/2016

#### Related information

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC0039940000) (initial marketing authorisation)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 04/10/2023

## Share this page

[Back to top](#main-content)